Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting.

Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. Abstract Text:

BACKGROUND AND OBJECTIVE: Cost control is becoming an increasingly important consideration for clinicians when planning how to provide the best treatment for anaemic cancer patients. Administration of erythropoiesis stimulating agents (epoetin alpha, epoetin beta and darbepoetin alpha) has become the standard of care for treatment of anaemia in cancer patients. However, only limited information is available on the economic comparability of epoetin alpha, epoetin beta and darbepoetin alpha, and thus this study was conducted to compare cost per patient of each of these agents for anaemic cancer patients. METHODS: All prescriptions of the agents over 1 year were analysed by two Austrian regional public health insurance associations and cost per patient for each agent was calculated from invoicing data. Data from the two regions were combined to obtain total mean drug costs per patient per year. RESULTS AND DISCUSSION: Analyses showed significantly lower costs for epoetin alpha ( 2,743.27 euros) than for darbepoetin alpha (3,627.98 euros ) or epoetin beta ( 3,292.28 euros): epoetin alpha vs. darbepoetin alpha (P < 0.0001); epoetin beta vs. darbepoetin alpha (P = 0.0001); epoetin alpha vs. epoetin beta (P = 0.0009). As costs of the three agents in Austria are identical for therapeutically equivalent doses, the higher cost of darbepoetin alpha was believed to be due mainly to longer treatment duration to target haemoglobin level. CONCLUSION: The finding of a cost difference favouring epoetin alpha over darbepoetin alpha suggests the need for prospective randomized studies comparing efficacy and cost effectiveness of all three agents to obtain more definitive data.

Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. Publishing Authors By Initials

For similar neoplasms research abstracts see: neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of clinical pharmacy and therapeutics

VOLUME: 31

Page Numbers: 503-12

Journal Abbreviation: J Clin Pharm Ther

ISSN: 0269-4727

DAY: 28

MONTH: Oct

YEAR: 2006

Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8704308

Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. Keywords Mesh Terms:

KEYWORDS: Neoplasms

MESH TERMS: complications

Chemical & Substance for Abstract: Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. Information

Substance Name: darbepoetin alfa

Registry Number: 209810-58-2

Grant and Affiliation Information for Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting.

AFFILIATION: Burgenländische Gebietskrankenkasse, Eisenstadt, Austria.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Pharm Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting Related Publications

• Atmospheric temperature profiling in the presence of clouds with a pure rotational Raman lidar by use of an interference-filter-based polychromator.
• Cadherins and catenins at synapses: roles in synaptogenesis and synaptic plasticity.
• Computation of optical motion by movement detectors.
• Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting.
• Deletion of Integrin-Linked Kinase from Skeletal Muscles of Mice Resembles Muscular Dystrophy Due to {alpha}7 1-Integrin Deficiency.
• Distinct roles of the beta 1-class integrins at the developing and the mature hippocampal excitatory synapse.
• Erbin controls dendritic morphogenesis by regulating localization of delta-catenin.
• Error analysis of Raman differential absorption lidar ozone measurements in ice clouds.
• Inhibition of Notch signaling biases rat thymocyte development towards the NK cell lineage.
• Novel Approaches to Imatinib- and Sunitinib-Resistant GIST.
• Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis.
• Quo vadis, genoma? A call to pipettes for biochemists.
• Realizing the full potential of the sequenced human genome.
• Retinal TrkB receptors regulate neural development in the inner, but not outer, retina.
• Silencing of the mineralocorticoid receptor by ribonucleic Acid interference in transgenic rats disrupts endocrine homeostasis.
• The ECM protein nephronectin promotes kidney development via integrin alpha8beta1-mediated stimulation of Gdnf expression.
• Unexpected biochemical and pharmacogenetic consequences of SNPs and haplotypes: a cautionary tale for human molecular genetics and epidemiology.
• [Colposcopical and cytological findings in 5046 female workers of the chemical industry]
• [Extended indications for cervix cerclage uteri in pregnancy]
• [Percutaneous transhepatic cholangiography and percutaneous transhepatic drainage]